Literature DB >> 22503666

Mortality and pituitary disease.

Paul M Stewart1, Mark Sherlock.   

Abstract

Outcome data from large series confirm increased mortality of patients with pituitary tumours, predominantly due to vascular disease. Control of cortisol secretion and growth hormone (GH) hypersecretion (together with cardiovascular risk factor reduction) is key in the normalisation of mortality rates in patients with Cushing's disease and acromegaly, respectively, though some excess mortality may persist even in "cured" patients.
Copyright © 2012. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Year:  2012        PMID: 22503666     DOI: 10.1016/j.ando.2012.03.026

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  3 in total

1.  Clinical score system in the treatment of Cushing's disease: failure to identify discriminative variables from the German Cushing's Registry.

Authors:  Mareike R Stieg; Matthias K Auer; Christina Berr; Julia Fazel; Martin Reincke; Stephanie Zopp; Alexander Yassouridis; Günter K Stalla
Journal:  Pituitary       Date:  2019-04       Impact factor: 4.107

2.  Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Authors:  Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers
Journal:  Endocr Relat Cancer       Date:  2017-07-21       Impact factor: 5.678

3.  Clinical evaluation of pituitary insufficiency in adult population

Authors:  Selvihan Beysel; Mustafa Çalişkan; Muhammed Kizilgül; Seyfullah Kan; Mustafa Özbek; Erman Çakal
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.